Executive Summary
- Morgan Stanley has reaffirmed its Overweight recommendation for Neurocrine Biosciences (NasdaqGS:NBIX).
- The analyst price target suggests a potential upside of 20.24%, reaching $169.88 per share.
- Institutional ownership has seen a slight increase, with total shares held by institutions growing by 4.44%.
- Despite positive analyst sentiment, the stock’s put/call ratio indicates a bearish options market outlook.
- Key institutional investors like Dodge & Cox and Jpmorgan Chase have recently increased their positions in NBIX.
Morgan Stanley Maintains ‘Overweight’ Rating on Neurocrine Biosciences
Fintel data indicates that on October 20, 2025, Morgan Stanley maintained its coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with an Overweight recommendation.
Analyst Price Forecast and Potential Upside
The average one-year price target for Neurocrine Biosciences, as of September 29, 2025, stands at $169.88 per share. This forecast offers a potential upside of 20.24% from its latest reported closing price of $141.28 per share. The price targets from analysts range from a low of $125.24 to a high of $210.00.
The projected annual revenue for Neurocrine Biosciences is $2,320 million, representing a decrease of 7.57%. The anticipated non-GAAP EPS is $9.22.
Fund Sentiment and Institutional Ownership
💡 The sentiment among funds and institutions regarding Neurocrine Biosciences is noteworthy. A total of 1,285 funds or institutions reported positions in NBIX, marking an increase of 14 owners or 1.10% in the last quarter. The average portfolio weight allocated to NBIX by all funds is 0.32%, an increase of 5.29% over the same period.
📍 Total shares held by institutions saw a significant increase of 4.44% in the last three months, reaching 124,618,000 shares. This upward trend in institutional holdings suggests growing confidence from major investors.
⚡ Despite the positive institutional investment trends, the put/call ratio for NBIX stands at 1.27. This figure suggests a predominantly bearish sentiment in the options market, where more put options (indicating bets on a price decrease) are being traded than call options.
Key Institutional Shareholder Activity
✅ Dodge & Cox holds 5,567,000 shares, representing 5.61% ownership. The firm increased its position by 0.58% from its previous filing and boosted its portfolio allocation in NBIX by 12.68% last quarter.
✅ Jpmorgan Chase holds 4,262,000 shares, accounting for 4.30% ownership. This represents a substantial increase of 37.33% in shares held and a 62.39% increase in portfolio allocation over the last quarter.
✅ Dodge & Cox Stock Fund (DODGX) holds 3,964,000 shares, or 4.00% ownership, with no reported change in the last quarter.
✅ iShares Core S&P Mid-Cap ETF (IJH) holds 3,224,000 shares, representing 3.25% ownership. While the number of shares decreased by 0.84%, the firm increased its portfolio allocation to NBIX by 6.24% last quarter.
✅ Vanguard Total Stock Market Index Fund Investor Shares (VTSMX) holds 3,187,000 shares, or 3.21% ownership. Shares held increased by 1.05%, and the fund’s allocation to NBIX grew by 2.47% in the past quarter.
Fintel’s Research Capabilities
Fintel is a comprehensive investment research platform serving individual investors, traders, financial advisors, and small hedge funds. The platform provides global data encompassing fundamentals, analyst reports, ownership details, fund sentiment, options sentiment, insider trading, options flow, and unusual options trades. Fintel also offers proprietary stock picks derived from advanced, backtested quantitative models aimed at enhancing profitability.
Key Insights
In summary, Morgan Stanley’s continued Overweight rating on Neurocrine Biosciences, coupled with a strong analyst price target, points to positive expectations for the stock’s performance. The increase in institutional ownership further supports this optimistic outlook. However, the current bearish trend in the options market, as indicated by the put/call ratio, introduces a note of caution for potential investors.